Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.48 |
| ▸ | RAB9A | P51151 | 4/20 | 0.48 |
| ▸ | MEN1 | O00255 | 4/20 | 0.48 |
| ▸ | MAPT | P10636 | 4/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.48 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.48 |
| ▸ | RELA | Q04206 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | STAT1 | P42224 | 1/20 | 0.48 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.48 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.48 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.48 |
| ▸ | AMY1A | P0DUB6 | 3/20 | 0.47 |
| ▸ | PIM1 | P11309 | 3/20 | 0.43 |
| ▸ | PIM3 | Q86V86 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5952580 | 0.87 | MAPT (0.45) | NPC1SMN1; SMN2RAB9AMEN1MAPT | |
| SCHEMBL5951537 | 0.85 | CBFB (0.44) | NPC1SMN1; SMN2RAB9AMEN1MAPT | |
| SCHEMBL546457 | 0.82 | AMY1A (0.49) | NPC1SMN1; SMN2RAB9AMEN1MAPT | |
| SCHEMBL5952684 | 0.82 | NPBWR1 (0.44) | NPC1SMN1; SMN2RAB9AMEN1MAPT | |
| SCHEMBL28498979 | 0.82 | ATM (0.39) | NPC1SMN1; SMN2RAB9AMEN1MAPT | |
| SCHEMBL28497076 | 0.82 | NPBWR1 (0.47) | NPC1SMN1; SMN2RAB9AMEN1MAPT | |
| SCHEMBL5952721 | 0.81 | RHEB (0.46) | NPC1SMN1; SMN2RAB9AMEN1MAPT | |
| SCHEMBL6276611 | 0.80 | NPBWR1 (0.49) | NPC1SMN1; SMN2RAB9AMEN1MAPT | |
| SCHEMBL5952633 | 0.80 | GUSB (0.48) | NPC1SMN1; SMN2RAB9AMEN1MAPT | |
| SCHEMBL5952765 | 0.80 | NPC1 (0.48) | NPC1SMN1; SMN2RAB9AMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060014756-A1 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2006-01-19 | — | — | US | claimed |
| US-6897208-B2 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2005-05-24 | — | — | US | claimed |
| EP-1441725-A1 | BENZIMIDAZOLES AND ANALOGUES AND THEIR USE AS PROTEIN KINASES INHIBITORS | Aventis Pharmaceuticals Inc. (US) | 2004-08-04 | — | — | EP | claimed |
| US-20040048868-A1 | Benzimidazoles | AVENTISUB LLC | 2004-03-11 | — | — | US | claimed |
| WO-2003035065-A1 | BENZIMIDAZOLES AND ANALOGUES AND THEIR USE AS PROTEIN KINASES INHIBITORS | AVENTIS PHARMACEUTICALS INC (US) | 2003-05-01 | — | — | WO | claimed |
| US-8288425-B2 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2012-10-16 | — | — | US | disclosed |
| US-8288425-B2 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2012-10-16 | — | — | US | disclosed |
| US-20060014756-A1 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2006-01-19 | — | — | US | disclosed |
| US-6897208-B2 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2005-05-24 | — | — | US | disclosed |
| EP-1441725-A1 | BENZIMIDAZOLES AND ANALOGUES AND THEIR USE AS PROTEIN KINASES INHIBITORS | Aventis Pharmaceuticals Inc. (US) | 2004-08-04 | — | — | EP | disclosed |
| US-20040048868-A1 | Benzimidazoles | AVENTISUB LLC | 2004-03-11 | — | — | US | disclosed |
| WO-2003035065-A1 | BENZIMIDAZOLES AND ANALOGUES AND THEIR USE AS PROTEIN KINASES INHIBITORS | AVENTIS PHARMACEUTICALS INC (US) | 2003-05-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014756-A1 | Benzimidazoles | CDK9, BMX, SBK3 | NPC1 3302/4885SMN1; SMN2 4210/4885RAB9A 810/4885 |
| US-20040048868-A1 | Benzimidazoles | CDK9, BMX, CDKN1A | NPC1 2551/4885SMN1; SMN2 3516/4885RAB9A 955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.